on DocMorris AG (isin : CH0042615283)
DocMorris Reports Significant Growth and Capital Increase
DocMorris AG reported a strong start to 2025 with a 13.4% overall growth in revenue across all business areas in the first quarter. Prescription medicine (Rx) sales alone rose by 52.3%. The company has secured a CHF 200 million capital increase fully underwritten by a banking consortium. This move aims to bolster medium-term Rx growth and marketing efforts until free cash flow breakeven is projected in 2027.
The TeleClinic division experienced over 100% growth, gearing up for further expansion. DocMorris anticipates an EBITDA margin of 8% and expects to reach EBITDA breakeven in 2026. The company foresees continued growth driven by a strong customer base and strategic advertising initiatives.
Capital raised is intended to support the ongoing Rx growth strategy and consider potential debt repayments. The upcoming Annual General Meeting will provide more details on the capital increase terms.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DocMorris AG news